Clinical Trial Search

Primary: The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline — -0.6; 1.83 ng/mL

Primary: Change From Baseline (100%) in Ratio of Bone Formation Marker to Bone Resorption Marker — 106.1; 103.6; 112.3; 113.0 percentage change from baseline

Primary: Change in C-terminal Telopeptide of Type I Collagen [CTX] — -4.1; 13.7; -7.7 percent change — p=0.611

Primary: Change in Hip Bone Mineral Density (BMD) — 0; -.03 g/cm2

Primary: Bone Mineral Density (BMD) of the Total Hip and Spine — 4.5; 0.7; 3.0; 1.1 Percent change

Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)

Primary: Sensitivity of the Density Index Against Dual Energy X-ray Absorptiometry for Detecting Osteoporosis — 93.7; 100 percentage of true positives

Primary: Relative Change in OPG/RANK/RANKL mRNA Expression in Isolated T Cells and Monocytes — 0.76 relative fold change — p=<0.05

Primary: Number Adherent With the Intervention — 29 participants

Primary: Non-vertebral Fracture Incidence — 70; 0 participants

Primary: Change in C-terminal Peptide of Type 1 Collagen (CTX) — 0.03; 0.03; 0.05; 0.03 ng/mL

Primary: Percentage Change in Lumbar Spine Bone Mineral Density (BMD) at Month 24 Relative to Baseline, by Stratum — 4.62; 4.03; -2.24; 5.60 Percentage change in BMD

Primary: Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD) — 0.059; 0.028 grams per square centimeters — p=<0.001

Primary: BMD of Spine by DXA — 2.269; -1.735 percentage change

Primary: Difference in Percent Change in Bone Mineral Density (BMD) From Baseline to 14 Weeks Between the Rosiglitazone Group and the Placebo Group — -1.3; 0.3 Percent change…

Primary: Percent Change in Bone Mineral Density From Baseline at the Lumbar Spine — 1.97; -2.32; 2.33; 0.7 Percent Change

Primary: Percentage of Participants With Modeling Based Bone Formation in the Femoral Neck — 100 percentage of participants

Primary: Bone Mineral Density — 3.2; -0.6 percent change — p=<0.0001

Primary: Postero-anterior Spine Bone Mineral Density by DXA — 0.891; 0.887; 0.874 g/cm2 — p=0.03

Primary: Bone Mineral Density (BMD) at Lumbar Spine (L1-L4) — 5.54; 5.39 percent

Primary: Mean Percent Change in BMD of the Lumbar Spine From Baseline to Month 12 — .94; 3.52 percent — p=<0.001

Primary: Bone Mineral Density (BMD) of the Lumbar Spine (Participants With Percentage Increase). — 11 participants

Primary: Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels — 0.092; 0.297; 0.122; 0.331 ng/ml

Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443

Primary: Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. — 0.76; 0.78; 0.88; 0.86 g/cm2

Primary: Changes in BMD at Femoral Neck — -3.2; 0.25 percentage of change in BMD — p=<0.05

Primary: Number of Participants That Initiate an Osteoporosis Prescription Medication — 157; 153 Participants

Primary: Change in Anterior-posterior Spine Bone Mass Density Measured by Dual Energy X-ray Absorptiometry (DXA) Compared to Baseline — 0.51; 0.51 percentage change

Primary: Mean % Change From Baseline in Trabecular Number (Tb.N) by HR-pQCT — 2.1; -0.6; 0.9; 4.1 Percent change

Primary: Changes in T-cell Activation Measured by Flow Cytometry, Specifically the Percentage of CD3+CD69+ T-cells — 3.6; 1.8 percentage of CD3 positive cells